Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease

Journal of Crohn's and Colitis

Volumn 4, Issue 6, 2010, Pages 623-628

  Pozler, O ^a   Chladek J ^b   Maly J ^a   Hroch, M ^b   Dedek P ^a   Beranek M ^a   Krasnicanova P ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Azathioprine; Children; Inflammatory bowel diseases; Steady state

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; BUDESONIDE; MERCAPTOPURINE; METHYLMERCAPTOPURINE; METRONIDAZOLE; PREDNISOLONE; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CHILD; ENTERITIS; ENZYME ACTIVITY; ERYTHROCYTE; ERYTHROCYTE LEVEL; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; NEWBORN; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEADY STATE;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; CHILD; CHILD, PRESCHOOL; FEMALE; GENOTYPE; GUANINE NUCLEOTIDES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; MALE; METHYLTRANSFERASES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; THIONUCLEOTIDES; TREATMENT OUTCOME;

EID: 78649515217     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2010.06.005     Document Type: Article

References (22)

1. Tiede I., Fritz G., Strand S., Poppe D., Dvorsky R., Strand D., et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003, 111:1133-1145.
2. Medical position paper: inflammatory bowel disease in children and adolescents: recommendations for diagnosis - The Porto Criteria. J Pediatr Gastroenterol Nutr 2005, 41:1-7. IBD working group of the European society of paediatric gastroenterology, hepatology nad nutrition (ESPGHAN).
3. Escher J.C., Taminiau J.A., Nieuwenhuis E.E., Büller H.A., Grand R.J. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 2003, 9:34-58.
4. Hyams J.S., Ferry G.D., Mandel F.S., Gryboski J.D., Kibort P.M., Kirschner B.S., et al. Development and validation of pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr 1991, 12:437-447.
5. Jacqz-Aigrain E., Bessa E., Medard Y., Mircheva Y., Vilmer E. Thiopurine methyltransferase activity in a French population: H.P.L.C. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol. 1994, 38:1-8.
6. Erb N., Haverland U., Harms D.O., Escherich G., Janka-Schaub G. High-performance liquid chromatographic assay of metabolites of thioguanine and mercaptopurine in capillary blood. J Chromatogr B Analyt Technol Biomed Life Sci. 2003, 796:87-94.
7. Fraser A.G., Orchard T.R., Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30year review. Gut 2002, 50:485-489.
8. Dubinsky M.C. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy and safety. Clin Gastroenterol Hepatol 2004, 2:731-743.
9. Al Hadithy A.F.Y., de Boer N.K.H., Derijks L.J., Escher J.C., Mulder C.J., Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005, 37:282-297.
10. Markowitz J., Grancher K., Kohn N., Lesser M., Daum F. A multicenter trial of 6-mercaptopurine and prednison in children with newly diagnosed Crohn's disease. Gastroenterology 2000, 119:895-902.
11. Sawczenko A., Lynn R., Sandhu B.K. Variations in initial assessment and management of inflammatory bowel disease across Great Britain and Ireland. Arch Dis Child 2003, 88:990-994.
12. Jaspers G.J., Verkade H.J., Escher J.C., de Ridder L., Taminiau J.A., Rings E.H. Azathioprine maintains first remission in newly diagnosed pediatric Crohn's disease. Inflamm Bowel Dis 2006, 12:831-836.
13. Markowitz J., Grancher K., Kohn N., Daum F. Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am J Gastroenterol 2002, 97:928-932.
14. Levine A., Milo T., Buller H.A., Markowitz J. Consensus and controversy in the management of pediatric Crohn disease: an international survey. J Pediatr Gastroenterol Nutr 2003, 36:464-469.
15. Present D.H., Korelitz B.I., Wisch N., Glass J.L., Sachar D.B., Pasternack B.S. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980, 302:981-987.
16. Hyams J.S. Inflammatory Bowel Disease. Nelson textbook of pediatrics 2007, 1575-1585. Saunders, Philadelphia. 18th ed. R.M. Kliegman, R.E. Behrman, H.B. Jenson, B.F. Stanton (Eds.).
17. Hindorf U., Lindqvist M., Peterson C., Söderkvist P., Ström M., Hjortswang H., et al. Pharmacogenetics during standardised iniciation of thiopurine treatment in inflammatory bowel disease. Gut 2006, 55:1423-1431.
18. Kwan L.Y., Devlin S.M., Mirocha J.M., Papadakis K.A. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease. Dig Liver Dis 2008, 40:425-432.
19. Derijks L.J.J., Gilissen L.P.L., Hooymans P.M., Hommes D.W. Review article: thiopurines in inflammatory bowel disease. Aliment Pharmacol Ther 2006, 24:715-729.
20. Van Os E.C., Zins B.J., Sandborn W.J., Mays D.C., Tremaine W.J., Mahoney D.W., et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996, 39:63-68.
21. Lowry P.W., Franklin C.L., Weaver A.L., Szumlanski C.L., Mays D.C., Loftus E.V., et al. Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut 2001, 49:393-396.
22. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., Vasiliauskas E.A. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.